Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 11/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 4/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6355213 | 0.90 | P2RX7 (0.56) | P2RX7POLBALDH1A1CCR1CCR2 | |
| SCHEMBL6355840 | 0.88 | P2RX7 (0.54) | P2RX7RORCALDH1A1 | |
| SCHEMBL6356252 | 0.86 | P2RX7 (0.66) | P2RX7ALDH1A1HTTL3MBTL1 | |
| SCHEMBL6357198 | 0.85 | P2RX7 (0.51) | P2RX7POLBCCR1CCR2HTT | |
| SCHEMBL6356231 | 0.79 | P2RX7 (0.58) | P2RX7ALDH1A1HTTL3MBTL1 | |
| SCHEMBL6357648 | 0.78 | P2RX7 (0.77) | P2RX7ALDH1A1HTTL3MBTL1 | |
| SCHEMBL6362555 | 0.76 | P2RX7 (0.54) | P2RX7ALDH1A1HTTL3MBTL1 | |
| SCHEMBL5917673 | 0.76 | P2RX7 (0.69) | P2RX7POLBCCR1CCR2 | |
| SCHEMBL5814945 | 0.76 | P2RX7 (0.66) | P2RX7POLB | |
| SCHEMBL6359688 | 0.75 | P2RX7 (0.54) | P2RX7POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | claimed |
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | TFAM, CYP11B2, CYP11B1 | P2RX7 448/4885POLB 1411/4885RORC 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.